Intermediate for Vorapaxar. Vorapaxar (trade name: Zontivity) is a thrombin receptor (protease-activated receptor, PAR-1) antagonist. Vorapaxar is a new anti-platelet drug that and is used for persons with a history of myocardial infarction (heart attack) or persons with peripheral arterial disease. Vorapaxar has been approved by the U.S Food and Drug Administration on May 5, 2014.
Product Name: (2E)-(R)-5-(Diphenylamino)-5-oxopent-3-en-2-yl 3-(5-nitrocyclohex-1-en-1-yl)acrylate
CAS Number: 900186-73-4
Molecular Weight:  446.5018
Molecular Formula:  C26H26N2O5
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.